(Total Views: 60)
Posted On: 05/16/2025 4:51:59 PM
Post# of 369
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations into the second half of 2026.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations into the second half of 2026.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
